Article
ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
PloS one - 1 Jan 2014
Damaj Gandhi, Joris Magalie, Chandesris Olivia, Hanssens Katia, Soucie Erinn, Canioni Danielle, Kolb Brigitte, Durieu Isabelle, Gyan Emanuel, Livideanu Cristina, Chèze Stephane, Diouf Momar, Garidi Reda, Georgin-Lavialle Sophie, Asnafi Vahid, Lhermitte Ludovic, Lavigne Christian, Launay David, Arock Michel, Lortholary Olivier, Dubreuil Patrice, Hermine Olivier
Abstract excerpt
Systemic mastocytosis with associated hematologic clonal non-mast cell disease (SM-AHNMD) is a rare and heterogeneous subtype of SM and few studies on this specific entity have been reported. Sixty two patients with Systemic mastocytosis with associated hematologic clonal non-mast cell disease (SM-AHNMD) were presented. Myeloid AHNMD was the most frequent (82%) cases. This subset of patients were older, had more...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.